GRATRY & Co LLC grew its holdings in Allergan PLC. (NYSE:AGN) by 61.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,713 shares of the company’s stock after acquiring an additional 3,692 shares during the period. Allergan PLC. comprises about 2.9% of GRATRY & Co LLC’s investment portfolio, making the stock its 9th biggest position. GRATRY & Co LLC’s holdings in Allergan PLC. were worth $2,361,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Veritas Asset Management LLP bought a new stake in Allergan PLC. during the first quarter worth approximately $761,339,000. Iridian Asset Management LLC CT increased its stake in Allergan PLC. by 141.3% during the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock worth $306,733,000 after acquiring an additional 751,848 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Allergan PLC. during the first quarter worth approximately $124,255,000. Vanguard Group Inc. increased its stake in Allergan PLC. by 2.2% during the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after acquiring an additional 482,220 shares during the last quarter. Finally, Blue Ridge Capital L.L.C. grew its stake in shares of Allergan PLC. by 24.1% during the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares during the last quarter. Institutional investors and hedge funds own 82.04% of the company’s stock.
Shares of Allergan PLC. (NYSE AGN) traded up 1.41% during midday trading on Friday, reaching $178.82. The company’s stock had a trading volume of 3,836,922 shares. The stock has a market capitalization of $59.78 billion, a price-to-earnings ratio of 5.45 and a beta of 1.15. The company has a 50 day moving average of $208.20 and a 200-day moving average of $229.12. Allergan PLC. has a 52 week low of $175.21 and a 52 week high of $256.80.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the firm earned $3.35 EPS. Allergan PLC.’s revenue was up 8.8% on a year-over-year basis. Equities research analysts predict that Allergan PLC. will post $16.21 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.57%. Allergan PLC.’s dividend payout ratio (DPR) is 9.95%.
Allergan PLC. declared that its Board of Directors has initiated a stock buyback program on Monday, September 25th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
ILLEGAL ACTIVITY WARNING: “GRATRY & Co LLC Buys 3,692 Shares of Allergan PLC. (AGN)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/allergan-plc-agn-position-raised-by-gratry-co-llc.html.
AGN has been the topic of a number of analyst reports. Morgan Stanley cut Allergan PLC. from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $284.00 to $228.00 in a research note on Wednesday, September 20th. J P Morgan Chase & Co set a $275.00 price objective on Allergan PLC. and gave the stock a “buy” rating in a research note on Sunday, October 22nd. Cowen and Company reissued an “outperform” rating and issued a $400.00 price objective on shares of Allergan PLC. in a research note on Tuesday, August 29th. Zacks Investment Research raised Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective on the stock in a research note on Tuesday, July 11th. Finally, Wells Fargo & Company reissued an “outperform” rating on shares of Allergan PLC. in a research note on Monday, September 11th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Allergan PLC. presently has a consensus rating of “Hold” and a consensus target price of $252.39.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.